Satellos to hold investor call on BASECAMP DMD pediatric study strategy
The company will host a conference call on Nov. 6, 2026, to update investors on the clinical and regulatory plans for its Phase 2 BASECAMP study.
Satellos Bioscience Inc. announced on Nov. 5, 2026, that it will host a conference call and audio webcast at 8:00 a.m. ET on Friday, Nov. 6, 2026, to provide an update on the clinical and regulatory strategy for BASECAMP, the company's Phase 2 pediatric study in boys ages 7, 8 or 9 with Duchenne muscular dystrophy (DMD).1
The call will include remarks from Satellos Co-founder and Chief Executive Officer Frank Gleeson and Chief Medical Officer Wildon Farwell, M.D.1 A live webcast with accompanying slides will be made available on the Events and Presentations page of the Investors section of the company's website1, and a replay will be available following the presentation.1
Satellos describes itself as a clinical-stage drug development company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases.1 Its lead candidate, forazapadin, is an orally administered small molecule AAK1 inhibitor designed to address deficits in muscle repair and regeneration.1 The drug is being evaluated as a potential disease-modifying treatment for DMD in two Phase 2 clinical trials, BASECAMP in pediatric participants with DMD and TRAILHEAD in adults living with DMD.1
Beyond DMD, Satellos has received clearance for an Investigational New Drug (IND) application to initiate clinical research into forazapadin for the treatment of facioscapulohumeral muscular dystrophy (FSHD).1 The company has also said it has identified additional muscle diseases and injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and plans to pursue these opportunities in future clinical development.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.